• Acridine Orange Hydrochloride: Evidence Scope

  2026-10-12

  Acridine Orange hydrochloride, listed by APExBIO as N3,N3,N6,N6-tetramethylacridine-3,6-diamine hydrochloride, is documented as a fluorescent nucleic-acid dye. The available evidence here is limited to supplier information describing identity, quality-control documentation, spectral behavior, and broad research contexts; no matched primary paper is available for independent assessment.

• KN-62: Evidence, Scope, and Boundaries

  2026-10-12

  KN-62 is presented by APExBIO as a CaMKII inhibitor, but the supplied evidence does not establish its effects in glioblastoma or validate broad claims about calcium signaling, secretion, metabolism, or cell-cycle control. The cited glioblastoma study concerns a different compound, NNC-55–0396, so its mechanistic findings should not be transferred to KN-62.

• Perospirone: Receptor and Kv1.5 Evidence

  2026-10-11

  Perospirone, also called SM-9018 free base, combines reported 5-HT2A and dopamine D2 antagonism with partial 5-HT1A agonism. A 2025 study additionally found concentration-dependent inhibition of voltage-gated K+ currents in freshly isolated rabbit coronary arterial smooth muscle cells, but the result does not establish a clinical vascular effect.

• WAY-100635 and Serotonin Signaling in Pain

  2026-10-10

  WAY-100635 offers a selective pharmacological lens for interpreting 5-HT1A signaling in pain and affective neuroscience. This article explains how its antagonist profile can help test mechanistic hypotheses raised by recent cannabidiol research without overstating what current evidence proves.

• Ziprasidone Augmentation in Anxious Depression

  2026-10-09

  This post-hoc moderator analysis examined whether anxious versus nonanxious depression altered the antidepressant or anxiolytic response to ziprasidone added to escitalopram. Depression outcomes were similar across subgroups, while the anxiety signal was not clinically meaningful, underscoring the limits of subgroup inference from a secondary analysis.

• Clozapine N-oxide and Circuit-Level Causal Inference

  2026-10-09

  Clozapine N-oxide (CNO) is more than a DREADDs activator: it is a tool for testing causal models of neuronal activity modulation. This article interprets the Wang et al. light-and-anxiety study through the lens of circuit specificity, evidence strength, and experimental limitations.

• Mianserin HCl: Evidence and Research Context

  2026-10-08

  Mianserin HCl is a tetracyclic antidepressant and reported 5-HT2 receptor antagonist used in neuroscience receptor modulation and psychiatric disorder research. Peer-reviewed cyclodextrin work shows that complexation can change, rather than uniformly reduce, mianserin-associated cytotoxicity in a Chinese hamster cell model.

• Perospirone: Receptor and Kv1.5 Pharmacology

  2026-10-08

  Perospirone is best understood through two evidence layers: established serotonergic and dopaminergic receptor pharmacology, and emerging evidence of vascular Kv1.5 channel inhibition. The latter finding is promising but remains preclinical and model-limited.

• Cannabidiol, Orofacial Pain, and Affective Circuits

  2026-10-07

  A 2026 Brain Research Bulletin study examined cannabidiol across sensory, affective, cognitive, inflammatory, endocannabinoid, and serotonergic dimensions of pain. Its main contribution is a multi-level preclinical framework showing that CBD reduced inflammatory pain-related abnormalities while engaging distinct peripheral and central mechanisms, although translation beyond mouse models remains uncertain.

• Deep Learning Detects Cardiotoxicity in iPSC-CMs

  2026-10-07

  Grafton et al. developed a high-content imaging framework that combines induced pluripotent stem cell-derived cardiomyocytes with deep-learning analysis to identify cellular patterns associated with drug-induced cardiotoxicity. The study supports earlier, target-agnostic safety assessment, while its image-based endpoint remains complementary to electrophysiology, contractility, and mechanistic assays rather than a replacement for them.

• Ginger Compounds and the Murine 5-HT3 Receptor

  2026-10-06

  Lohning, Marx, and Isenring used molecular docking and GRID analysis to examine how gingerols, shogaols, and related compounds may interact with orthosteric and proposed allosteric regions of the murine 5-HT3 receptor. Their results support a mechanistic hypothesis for ginger-derived 5-HT3 receptor antagonism, but the computational evidence does not by itself establish clinical efficacy or direct receptor affinity.

• Sumatriptan Metabolism Revisited: CYP and MAO Evidence

  2026-10-06

  Pöstges and Lehr revisited the accepted view that sumatriptan is metabolized mainly through monoamine oxidase A, showing that selected CYP enzymes also produce sequential N-desmethyl metabolites. Their recombinant-enzyme and HPLC-MS evidence supports a more flexible metabolic model, while its direct applicability to human pharmacokinetics remains limited.

• Cannabidiol, Orofacial Pain, and Affective Recovery

  2026-10-05

  A 2026 Brain Research Bulletin study reports that cannabidiol (CBD) reduced acute and chronic inflammatory pain in mice while also improving pain-related affective and cognitive abnormalities. Its main innovation is a multi-level analysis linking peripheral inflammation, central pain circuits, endocannabinoid signaling, and serotonin activity without treating sensory analgesia as the only meaningful outcome.

• CRISPR Repair Outcomes in Nondividing Cells

  2026-10-05

  A source-grounded overview of how nondividing human cells repair CRISPR-induced DNA damage, what the 2025 Nature Communications study found, and where its evidence does—and does not—support translational interpretation.

• Palonosetron Hydrochloride: CINV and RINV Evidence

  2026-10-04

  The 2013 review by Fabi and Malaguti positioned palonosetron hydrochloride as a distinctive 5-HT3 receptor antagonist because its high receptor affinity and prolonged half-life may improve control of delayed chemotherapy-induced nausea and vomiting. Its main practical implication is evidence-based placement within antiemetic strategies, while also highlighting unresolved questions for radiotherapy, multi-day chemotherapy, and combination treatment.

7965 records 1/531 page Next 12345 下5页 Last page